Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06752356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 2026 to Oct 2026
    • Study sites: 3 to 5
    v13
  2. Start date: Jun 2026 to Aug 2026v12
  3. Study sites: 2 to 3v11
  4. Eligibility criteria expanded, about 258 words
    • Study title expanded, about 2 words
    v10
  5. Start date: Apr 2026 to Jun 2026v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 1 to 2v8
  2. Start date: Jan 2026 to Apr 2026v7
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v6
  4. Start date: Nov 2025 to Jan 2026v5
  5. Start date: Sep 1, 2025 to Nov 2025v4
  6. Re-verified, no change to tracked fieldsv3
  7. Eligibility criteria revised
    • Secondary endpoints: 1 to 9
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kedrion S.p.A.
6 trials monitored
See 1 trial at risk
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Trial Details
NCT Number NCT06752356
Lead Sponsor Kedrion S.p.A.
Conditions
(from sponsor)		 Chronic Inflammatory Demyelinating Polyneuropathy
Related terms Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 161 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov